Supervised injection site

Government of Canada signs agreements with Yukon delivering nearly $86 million to improve health care

Retrieved on: 
Tuesday, March 12, 2024
Dignity, Transfer, Government, Icelandic, Capacity building, Indigenous peoples, Communication, Bed, Federation, Nation, Education, Nursing, Patient, Mental health, The Honourable, Working Together, Hospital, Long-term care, CHT, Ageing, Life, Outline, Council, Supervised injection site, Social services, Investment, Safety, YT, Geography, IPM, Recruit

Today, the Honourable Mark Holland, Canada's Minister of Health and the Honourable Tracy-Anne McPhee, Minister of Health and Social Services of the Yukon, announced three agreements to invest a total amount of nearly $86 million to improve health care access and services in the Yukon.

Key Points: 
  • Today, the Honourable Mark Holland, Canada's Minister of Health and the Honourable Tracy-Anne McPhee, Minister of Health and Social Services of the Yukon, announced three agreements to invest a total amount of nearly $86 million to improve health care access and services in the Yukon.
  • Establish a new walk-in primary care clinic in Whitehorse to provide accessible and essential non-urgent health care services.
  • The THIF supports the territories, which face higher costs compared to the provinces in delivering health care, by providing funding for crucial health care system improvements , innovative health care projects and ensuring stable funding for necessary costs, including medical travel.
  • They will expand primary care, enhance long-term care, home care, and community care, address the substance use health emergency, support health system transformation, and tackle health workforce shortages.

Ashley & City of Hope Launch Campaign to Raise Awareness for National Diabetes Month

Retrieved on: 
Wednesday, November 2, 2022
Awareness, Publication, CEO, Knowledge, National Cancer Institute, YouTube, Type 2 diabetes, Biomarker, Ashley Furniture Industries, Research, Cancer, Time, LLC, Organization, Supervised injection site, Cancer Treatment Centers of America, Disease, Love, Immunotherapy, CAR, Translational Genomics Research Institute, Haematopoietic system, Incidence, Technology, Foundation, Learning, City, Gene editing, Insulin, Patient, Multimedia, City of Hope National Medical Center, City of Hope, Pharmaceutical industry, Public relations, Hope, Facebook, Diabetes, Pinterest

TAMPA, Fla., Nov. 2, 2022 /PRNewswire/ -- Ashley Global Retail (Ashley) is joining forces with City of Hope, one of the largest cancer research and treatment organizations in the United States, to raise awareness about diabetes during National Diabetes Month.

Key Points: 
  • TAMPA, Fla., Nov. 2, 2022 /PRNewswire/ -- Ashley Global Retail (Ashley) is joining forces with City of Hope, one of the largest cancer research and treatment organizations in the United States, to raise awareness about diabetes during National Diabetes Month.
  • City of Hope is a global leader in diabetes its scientists helped develop synthetic human insulin, now used by millions of people with diabetes.
  • The co-branded campaign with Ashley aims to feature City of Hope's expertise and groundbreaking milestones as well as to raise funds toward new medical advancements.
  • Ashley Furniture Industries, LLC will also host the awareness campaign across its North American facilities, engaging over 15,000 employees in learning more about diabetes, research efforts and prevention measures.

Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results

Retrieved on: 
Monday, November 15, 2021
Population, Safety, AES, Drug, PK, Adolescence, General Administration of Sport of China, Private Securities Litigation Reform Act, Therapy, Immunodeficiency, Infection, Disease, Research and development, Food, AZD1222, Severe acute respiratory syndrome coronavirus 2, Treatment, Serum, Research, IV, Forward-looking statement, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Epitope, Human, Vaccine, GLOBE, Half-life, Antibody, SEC, Supervised injection site, EUA, United States Patent and Trademark Office, Patent, Nasdaq, Patient, FDA, Adult, Pharmaceutical industry, Lithium

WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today provided an update on its lead COVID-19 antibody program, ADG20, and reported third quarter 2021 financial results. ADG20 is an investigational monoclonal antibody product candidate designed to provide broad and potent neutralizing activity against SARS-CoV-2, including variants of concern, for the prevention and treatment of COVID-19.

Key Points: 
  • ADG20 is an investigational monoclonal antibody product candidate designed to provide broad and potent neutralizing activity against SARS-CoV-2, including variants of concern, for the prevention and treatment of COVID-19.
  • Further, our single injection delivery avoids the inconveniences associated with IV administration or multiple injections, said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio.
  • Certain patient populations may not be ideal candidates for emerging oral treatment options due to adherence concerns, comorbidities or possible drug interactions.
  • Research & development expenses including in-process research and development for the third quarter of 2021 were $49.4 million.

Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19

Retrieved on: 
Wednesday, September 29, 2021
Infection, Therapy, Safety, Serum, Pharmacokinetics, PK, AZD1222, Private Securities Litigation Reform Act, Conference, Half-life, Patient, Emergency Use Authorization, Epitope, GLOBE, Antibody, EUA, Disease, Infectious Diseases Society of America, Risk, COVID-19, Human, Severe acute respiratory syndrome coronavirus 2, Research, AES, Coronavirus, Forward-looking statement, Nasdaq, SEC, Supervised injection site, Treatment, Pharmaceutical industry, Vaccine

WALTHAM, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced new data from the company’s COVID-19 antibody program. Updated, six-month data from its ongoing Phase 1 study of ADG20 in healthy participants and data validating the selection of the 300 mg intramuscular (IM) dose given as a single injection that is being evaluated in the company’s ongoing global Phase 2/3 treatment (STAMP) and prevention (EVADE) clinical trials will be presented during four poster sessions at the Infectious Disease Society of America’s IDWeek 2021, being held from Sept. 29 – Oct. 3, 2021. In addition, Adagio’s chief scientific officer, Laura Walker, Ph.D., will present a subset of the ADG20 Phase 1 data as well as background on the identification and optimization of this differentiated antibody clinical candidate in an oral presentation at the 19th Annual Discovery on Target Conference on Sept. 30, 2021.

Key Points: 
  • These Phase 1 data combined with our dose selection strategy, which relied on our innovative modeling approach, have allowed us to initiate and advance our pivotal trials of ADG20 in the treatment and prevention of COVID-19.
  • We anticipate these data will support an Emergency Use Authorization (EUA) application in the first quarter of 2022, which could enable us to bring an important treatment option to patients.
  • Adagio is evaluating ADG20 in a Phase 1 randomized, double-blind, placebo-controlled single ascending-dose study to assess safety and tolerability, pharmacokinetics (PK), immunogenicity, and serum virus neutralizing activity of ADG20 ex vivo against SARS-CoV-2.
  • Data from a six-month evaluation timepoint confirmed the extended half-life of ADG20, which approached 100 days based on data from the 300 mg IM dose that was given as a single injection.

Bright Minds Biosciences Provides Scientific Update

Retrieved on: 
Wednesday, September 22, 2021
RATS, Lists of diseases, News, Medical college, Chronic pain, Medical College of Wisconsin, Epilepsy, Depression, National, Neurological disorder, API, CSE, Disorder, Chemotherapy-induced peripheral neuropathy, Champaign County, Illinois, Board, Treatment, Toxicity, Supervised injection site, Emotional and behavioral disorders, CEO, University, Company, Pain, University of California, San Diego, Mental health, Service, Dravet syndrome, Research, Drug development, Headache, Drug discovery, PTSD, Safety, Forward-looking statement, Psilocybin, Howard Brody, Option, GLOBE, Director, Pharmaceutical industry, Risk management, Medical device

VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (Bright Minds, BMB or the Company) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today provided an update of significant scientific developments.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (Bright Minds, BMB or the Company) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today provided an update of significant scientific developments.
  • Over the past few months, we have dramatically improved BMBs competitive position with our therapeutic categories, as well as our broader capital markets strategy, stated Ian McDonald, CEO of Bright Minds.
  • This compound and its analogues were first invented by Bright Minds Chief Scientific Officer, Dr. Alan Kozikowski and Dr. Jianjun Cheng at the University of Illinois in Chicago.
  • Bright Minds Biosciences Inc. (the Company) has engagedIn-Site Communications Inc. (In-Site), previous service provider of the Company, for a 12-month term ending on March 30, 2022.

Government of Canada supports expansion of innovative safer supply project to operate in four cities across Canada

Retrieved on: 
Tuesday, March 2, 2021
Psychoactive drugs, Drug culture, Substance abuse, Drugs, Public health, Morphinans, Drug overdose, Psychiatric diagnosis, Heroin, Opioid epidemic in the United States, Supervised injection site

The Government of Canada continues to support communities as they respond to drug overdoses during the pandemic and beyond.

Key Points: 
  • The Government of Canada continues to support communities as they respond to drug overdoses during the pandemic and beyond.
  • With this investment, MySafe will be able to operate five sites in four cities across Canada.
  • As with other safer supply models funded by Health Canada, the patients are supervised by a healthcare practitioner and connected with important health and social services, including treatment.
  • Through these innovative projects, we are helping people at risk of overdose in Atlantic Canada access needed medication and supports."

An open letter from Darryl Tempest – Executive Director of the Canadian Vaping Association

Retrieved on: 
Tuesday, February 16, 2021
Psychoactive drugs, Drugs, Electronic cigarettes, Tobacco, Euphoriants, Smoking cessation, Drug culture, Electronic cigarette, Fentanyl, Supervised injection site, Heroin, Cocaine

The government responded by creating safe injection sites and are now considering decriminalizing heroine, fentanyl and cocaine.

Key Points: 
  • The government responded by creating safe injection sites and are now considering decriminalizing heroine, fentanyl and cocaine.
  • These measures were designed to provide safe spaces for addicts and to connect them with needed resources.
  • In large part, the confusion surrounding vaping stems from legitimate concerns regarding increased youth vaping rates.
  • These campaigns are contrary to the fact that vaping is the most successful tool in history to address smoking rates.

Government of Canada begins consultation to better ensure the continuity of supervised consumption sites and services in Canada

Retrieved on: 
Thursday, August 20, 2020
Psychoactive drugs, RTT, Drug culture, Morphine, Opioids, Medical emergencies, Heroin, Drug overdose, Supervised injection site, Opioid epidemic

OTTAWA, ON, Aug. 20, 2020 /CNW/ -Supervised consumption sites and services are an integral part of the Government of Canada's response to the opioid overdose crisis.

Key Points: 
  • OTTAWA, ON, Aug. 20, 2020 /CNW/ -Supervised consumption sites and services are an integral part of the Government of Canada's response to the opioid overdose crisis.
  • On August 15, 2020, Health Canada launched a 60-day consultation process on supervised consumption sites and services to evaluate what is working and what can be improved.
  • "The evidence shows us that supervised consumption sites and services save lives and can provide people who use drugs with access to health and social services and treatment.
  • Since January 1, 2016, the number of supervised consumption sites operating in Canada has increased from 1 to 38.

Emergency Shelter / Urgent Public Health Need Site National Community of Practice HUB

Retrieved on: 
Friday, June 19, 2020
Drug culture, Harm reduction, Prevention of HIV/AIDS, Substance dependence, Supervised injection site, Vancouver, Peter Jepson-Young, Public health, Social issues, Medicine

VANCOUVER, BC, June 18 2020 /CNW/ - The Dr. Peter Centre is creating a Community of Practice Hub for frontline service providers, health care professionals, and policymakers with the goal of building capacity within emergency shelters where people may need to use drugs and/or Urgent Public Health Need Sites (also known as Overdose Prevention Sites).

Key Points: 
  • VANCOUVER, BC, June 18 2020 /CNW/ - The Dr. Peter Centre is creating a Community of Practice Hub for frontline service providers, health care professionals, and policymakers with the goal of building capacity within emergency shelters where people may need to use drugs and/or Urgent Public Health Need Sites (also known as Overdose Prevention Sites).
  • The capacity building initiative will be national in reach in both English and French.
  • "Increased overdose deaths in Vancouver prompted the Dr. Peter Centre to use funds from Health Canada's Substance Use and Addictions Program (SUAP) to create the Community of Practice Hub.
  • Health Canada is supporting the Dr. Peter Centre for the Centre's first-in-North America supervised injection site experience, and its subsequent learning and teaching.

Pennsylvania's Largest Physician Organization Endorses Pilot Program of Safe Injection Sites to Combat Opioid Crisis

Retrieved on: 
Thursday, November 21, 2019
Psychoactive drugs, Drug culture, Morphine, Organic compounds, Morphinans, Harm reduction, Prevention of HIV/AIDS, Supervised injection site, Opioid epidemic, Injection, Heroin, Drug overdose

The Philadelphia non-profit Safehouse has faced court challenges in its attempt to build the first safe injection site in Pennsylvania.

Key Points: 
  • The Philadelphia non-profit Safehouse has faced court challenges in its attempt to build the first safe injection site in Pennsylvania.
  • "The opioid epidemic is the biggest public health crisis we've faced as a state in decades," said PAMED President Lawrence John, MD.
  • Studies from those countries show that safe injection sites can reduce overdose deaths, disease transmission, injection-related infections, and emergency department utilization.
  • This is our chance to definitively give it to them and help bring safe injection sites to America."